While there was insufficient efficacy to proceed with development of Lu AG06466 in Tourette Syndrome, the safety and tolerability of the agent was such that further investigational studies in additional indications will proceed.
The randomized, double blind, placebo controlled and with individual dose titration clinical trial enrolled 48 patients at multiple sites in
Dr.
"This is the first study in a novel biology and so while we hoped it would yield a positive result, I think it is important to note that further exploration both of this molecule and the endocannabinoid biology will continue. The research ongoing at
Lundbeck is planning investigational studies in other indications in neurology and psychiatry both with Lu AG06466 and with additional compounds generated by
About Lu AG06466 (former ABX-1431)
Lu AG06466 is an inhibitor of the monoacylglycerol lipase (MAGL) and selective modulator of the endocannabinoid system, and thereby works to reduce excessive neurotransmission and neuroinflammation that are known pathophysiological hallmarks for a range of psychiatric and neurological disorders.
Contacts
Media:
Journalist, Corp. Communication Senior Director, Corp. Communication
mbap@lundbeck.com mavk@lundbeck.com
+45 30 83 20 44 +45 36 43 40 00
Investors:
Palo@lundbeck.com
+45 30 83 24 26
About Lundbeck
An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases - we call this Progress in Mind.
Read more at www.lundbeck.com/global/about-us/progress-in-mind (https://webmaster.lundbeck.com/N2/Content/wwww.lundbeck.com/global/about-us/progress-in-mind).
Our approximately 5,800 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centres in
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck (https://twitter.com/lundbeck) and via LinkedIn (https://www.linkedin.com/company/lundbeck/).
Ottiliavej 9, 2500 Valby,
+45 3630 1311
info@lundbeck.com
https://news.cision.com/h--lundbeck-a-s/r/lundbeck-announces-phase-iia-study-results-of-lu-ag06466-in-adults-with-tourette-syndrome,c3073993
https://mb.cision.com/Main/18215/3073993/1219672.pdf
(c) 2020 Cision. All rights reserved., source